Guangzhou Wondfo Biotech Co.,Ltd

SZSE:300482 Stock Report

Market Cap: CN¥11.3b

Guangzhou Wondfo BiotechLtd Future Growth

Future criteria checks 5/6

Guangzhou Wondfo BiotechLtd is forecast to grow earnings and revenue by 27.5% and 21.1% per annum respectively. EPS is expected to grow by 26.9% per annum. Return on equity is forecast to be 13.9% in 3 years.

Key information

27.5%

Earnings growth rate

26.9%

EPS growth rate

Medical Equipment earnings growth25.7%
Revenue growth rate21.1%
Future return on equity13.9%
Analyst coverage

Low

Last updated19 Dec 2024

Recent future growth updates

Recent updates

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

Nov 18
Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Shareholders May Want To Dig Deeper Than Statutory Profit

Nov 01
Guangzhou Wondfo BiotechLtd's (SZSE:300482) Shareholders May Want To Dig Deeper Than Statutory Profit

Cautious Investors Not Rewarding Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Performance Completely

Sep 06
Cautious Investors Not Rewarding Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Performance Completely

Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

Jul 27
Returns On Capital At Guangzhou Wondfo BiotechLtd (SZSE:300482) Paint A Concerning Picture

Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations

Apr 29
Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations

A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price

Mar 27
A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price

There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital

Feb 29
There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital

Earnings and Revenue Growth Forecasts

SZSE:300482 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,7751,013N/A1,0864
12/31/20253,951818N/A9174
12/31/20243,265649N/A9274
9/30/20242,942524107538N/A
6/30/20242,852509230624N/A
3/31/20242,794502289664N/A
12/31/20232,765488-104329N/A
9/30/20232,989357116569N/A
6/30/20233,136354-56459N/A
3/31/20233,8874971,2681,818N/A
1/1/20235,6811,1971,0991,682N/A
9/30/20225,5501,2479051,472N/A
6/30/20225,5381,2578981,461N/A
3/31/20225,2901,383-270287N/A
12/31/20213,361634208665N/A
9/30/20213,14569518621N/A
6/30/20213,060741-1557N/A
3/31/20212,956692113594N/A
12/31/20202,8116346421,062N/A
9/30/20202,821663657886N/A
6/30/20202,7116308851,053N/A
3/31/20202,172413595775N/A
12/31/20192,072387131310N/A
9/30/20191,921375175329N/A
6/30/20191,817352137296N/A
3/31/20191,74832597232N/A
12/31/20181,650308117248N/A
9/30/20181,54228069198N/A
6/30/20181,498264N/A175N/A
3/31/20181,323231N/A186N/A
12/31/20171,145211N/A169N/A
9/30/2017921181N/A51N/A
6/30/2017747174N/A100N/A
3/31/2017624154N/A116N/A
12/31/2016547145N/A112N/A
9/30/2016525158N/A143N/A
6/30/2016486147N/A141N/A
3/31/2016450131N/A145N/A
12/31/2015429125N/A132N/A
9/30/2015382106N/A108N/A
6/30/2015380105N/A99N/A
3/31/201536596N/A107N/A
12/31/201436598N/A104N/A
12/31/201324859N/A101N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300482's forecast earnings growth (27.5% per year) is above the savings rate (2.8%).

Earnings vs Market: 300482's earnings (27.5% per year) are forecast to grow faster than the CN market (25.5% per year).

High Growth Earnings: 300482's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300482's revenue (21.1% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 300482's revenue (21.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300482's Return on Equity is forecast to be low in 3 years time (13.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:20
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guangzhou Wondfo Biotech Co.,Ltd is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue GaoChangjiang Securities Co. LTD.
Pei ChengChina Galaxy Securities Co., Ltd.
Jingwei QiChina Merchants Securities Co. Ltd.